Table 1.
Demographics of the study cohort
| Total Cohort (n = 457) | Patients without Complete Data (n = 157) | Patients with Complete Data (n = 300) | P-value | |
|---|---|---|---|---|
| Age at RP, years (mean, SD) (n = 457) | 62.0 (5.8) | 61.62 (6.0) | 61.65 (5.6) | 0.953a |
| Preoperative PSA, ng/ml (n, %) (n = 457) | ||||
| ≤10.0 | 294 (69.2) | 80 (70.4) | 206 (68.7) | 0.443b |
| 10.1–20.0 | 96 (22.6) | 30 (24.0) | 66 (22.0) | |
| >20.0 | 35 (8.2) | 7 (5.6) | 28 (9.3) | |
| Grade group at RP (n, %) (n = 457) | ||||
| 1 | 168 (36.8) | 65 (41.4) | 103 (34.3) | 0.294b |
| 2 | 134 (29.3) | 48 (30.6) | 86 (28.7) | |
| 3 | 63 (13.8) | 20 (12.7) | 43 (14.3) | |
| 4 | 70 (15.3) | 17 (10.8) | 53 (17.7) | |
| 5 | 22 (4.8) | 7 (4.5) | 15 (5.0) | |
| pT (n, %) (n = 440) | ||||
| 2 | 233 (53.0) | 72 (51.4) | 161 (53.7) | 0.785b |
| 3a | 153 (34.8) | 52 (37.1) | 101 (33.7) | |
| 3b | 54 (12.2) | 16 (11.5) | 38 (12.6) | |
| Lymph node status (n, %) (n = 454) | ||||
| Negative | 434 (95.6) | 150 (97.4) | 284 (94.7) | 0.230b |
| Positive | 20 (4.4) | 4 (2.6) | 16 (5.3) | |
| Follow-up time after RP, yr (median, range) (n = 457) | 9.5 (0.2–14.0) | 10.17 (0.6–13.99) | 9.52 (0.73–13.97) | 0.006a |
| Biochemical recurrence (n, %) (n = 457) | 110 (24.1) | 37 (23.7) | 73 (24.3) | 0.909b |
| Death from any cause (n, %) (n = 457) | 73 (16.0) | 21 (13.4) | 52 (17.3) | 0.286b |
| Death from prostate cancer (n, %) (n = 457) | 19 (4.2) | 8 (5.1) | 11 (3.7) | 0.468b |
| Patients receiving secondary therapy after RP (n, %) (n = 438) | 136 (31.1) | 42 (28.0) | 94 (32.6) | 0.330b |
| STAT5 IHC (n, %) (n = 417) | ||||
| Negative | 254 (60.9) | 74 (63.2) | 180 (60.0) | 0.576b |
| Positive | 163 (39.1) | 43 (36.8) | 120 (40.0) | |
| STAT5 FISH (n, %) (n = 376) | ||||
| Negative | 282 (75.0) | 61 (80.3) | 221 (73.7) | 0.300b |
| Positive | 94 (25.0) | 15 (19.7) | 79 (26.3) |
RP, radical prostatectomy; PSA, prostate specific antigen; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization;
a
Student’s t-test,
b
Fisher’s exact test.